Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study

To the Editor: Rituximab has been recommended as a first-line treatment for pemphigus, an autoimmune mucocutaneous disease.1 The conventional protocols of rituximab in pemphigus are commonly followed, including rituximab 1000 mg administered intravenously on days 1 and 15 or rituximab 375 mg/m2 administered intravenously once a week for 4 weeks, whereas small studies have proposed a low-dose protocol with rituximab 500 mg administered intravenously on days 1 and 15.2 Nevertheless, a lack of consensus on the dose and administration interval of rituximab in pemphigus remains.